Medicaid AMPs – PBMs out, mail order in
Executive Summary
Calculation of average manufacturer prices for Medicaid will generally exclude discounts to pharmacy benefit managers, CMS says. Final AMP rules will be published in the July 17 Federal Register. In Dec. 22, 2006 proposed rules, CMS expressed interest in including PBM discounts in AMPs and sought input on the feasibility of tracking them (1"The Pink Sheet" Jan. 1, 2007, p. 21). As proposed, AMPs will include sales to mail-order pharmacies. Also included are sales to home infusion and specialty pharmacies...
You may also be interested in...
Medicaid AMPs May Include More PBM Discounts, If CMS Can Figure Out How
CMS wants to include a broader array of pharmacy benefit manager price concessions in calculating Medicaid average manufacturer prices for reimbursing outpatient prescription drugs
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.